财务总监辞职，总经理暂代职责 2025 年 9 月 2 日，东北制药集团股份有限公司（以下简称 "东北制药"）发布官方公告，披露核心管理岗位人事调整：公司财务总监周雅娜女士因个人原因 申请辞去财务总监职务。根据公告安排，在公司正式聘任新财务总监前，将由董事、总经理蔡永刚先生代为行使财务总监职责，以保障财务工作的正常推 进。 根据东北制药 2025 年半年报数据，公司上半年经营业绩呈现 "营收净利润双下滑、研发投入高增长" 的特点：上半年实现营业收入 38.53 亿元，同比下滑 7.58%；归属于上市公司股东的净利润 1.29 亿元，同比下滑 17.62%，业绩承压明显。同期研发费用达 8349 万元，较去年同期大幅增长 84.09%，研发费用占 营业收入的比例约为 2.17%，反映出公司在创新领域的投入力度持续加大，试图通过研发突破缓解业绩压力。 关键岗位调整频繁，与战略及行业环境相关 此次财务总监变动并非个例，过去三年间，东北制药管理层关键岗位调整较为频繁，涉及董事、董事会秘书、副总经理、董事长等多个核心职位，具体变动 如下： 对于管理层频繁变动的原因，东北制药表示，部分调整源于公司战略优化需求及行业环境变 ...

截至2025年8月19日15时28分，亨迪药业股价报18.80元，较前一交易日上涨0.43%，成交额1.13亿元。 亨迪药业属于化学制药行业，主营业务涵盖原料药及制剂的研发、生产和销售。公司产品涉及解热镇痛 类、抗感染类等领域。 8月19日，亨迪药业发布公告称，2025年中期拟以资本公积金向全体股东每10股转增4.5股，未安排现金 分红。2025年中期，公司实现营收2.35亿元，归母净利润1855万元。 当日主力资金净流入901.43万元，占流通市值的0.17%；近五日主力资金净流出1559.61万元，占流通市 值的0.29%。 风险提示：股市有风险，投资需谨慎。 来源:金融界 ...

Group 1 - As of August 7, 2025, the stock price of Peking University Pharmaceutical is 6.81 yuan, down 1.02% from the previous trading day, with a trading volume of 146 million yuan and a turnover rate of 3.58% [1] - Peking University Pharmaceutical operates in the chemical pharmaceutical industry, with main business areas including pharmaceutical manufacturing, pharmaceutical distribution, and medical services. The company's products cover multiple therapeutic areas such as anti-infection, cardiovascular, and digestive systems [1] - As of July 31, 2025, the total number of shareholders is 53,400, an increase of 10.77% from the previous period. The average number of shares held per shareholder has decreased to 11,200 shares, with an average market value of 77,100 yuan, which is below the average level of the pharmaceutical and biotechnology industry [1] Group 2 - On August 7, 2025, the net outflow of main funds is 12.88 million yuan, with a cumulative net outflow of 50.01 million yuan over the past five days [1]

Group 1 - The core viewpoint of the news is that Taiji Group (600129.SH) announced a share repurchase plan to boost market confidence amid significant performance declines [1][2] - The company plans to repurchase shares worth between 80 million yuan and 120 million yuan, with a maximum repurchase price of 28.03 yuan per share, and the repurchase period is set for 12 months from the approval date [1][2] - The estimated number of shares to be repurchased ranges from approximately 285,410 to 428,110 shares, accounting for about 0.51% to 0.77% of the company's total share capital [1] Group 2 - Taiji Group's stock price has decreased approximately 68% from its peak of 68.14 yuan per share on May 31, 2023, to 21.76 yuan per share as of July 16, 2023 [2] - The company reported a 20.72% year-on-year decline in revenue for 2024, totaling 12.386 billion yuan, and a drastic 96.76% drop in net profit attributable to shareholders, amounting to 26.6527 million yuan [2] - For the first half of 2025, the company anticipates a net profit of approximately 139 million yuan, reflecting a year-on-year decline of about 71.9% [2] Group 3 - Despite the pressure on performance and costs, the company continues to invest in research and development, focusing on product re-development and new product innovation [3] - Taiji Group is also enhancing its marketing reform and operational control while strictly managing shipments to improve sales performance [3] - The company expects non-recurring gains and losses to impact net profit attributable to shareholders by approximately 19 million yuan, a decrease of about 5.5 million yuan compared to the previous year [3]